A Phase 2b, Randomized, Double-Blind, Placebo- Controlled, Multicenter Study to Assess the Safety, Efficacy and Pharmacokinetics of RNIB21 in the Treatment of Patients With Irritable Bowel Syndrome With Diarrhea (IBS-D)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT06727422

Title field or adapter rule

{'original_value': 'A Phase 2b, Randomized, Double-Blind, Placebo- Controlled, Multicenter Study to Assess the Safety, Efficacy and Pharmacokinetics of RNIB21 in the Treatment of Patients With Irritable Bowel Syndrome With Diarrhea (IBS-D)', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-10-31T23:27:35.499303+00:00

Published At

2026-04-20T00:00:00+00:00

Record Updated At

2026-04-20

Source Retrieved At

2026-10-31T22:18:52.668840+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["IBS (Irritable Bowel Syndrome)", "IBS-D (Diarrhea-predominant)"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-04-20", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT06727422"

protocolSection.identificationModule.officialTitle

"A Phase 2b, Randomized, Double-Blind, Placebo- Controlled, Multicenter Study to Assess the Safety, Efficacy and Pharmacokinetics of RNIB21 in the Treatment of Patients With Irritable Bowel Syndrome With Diarrhea (IBS-D)"

protocolSection.statusModule.overallStatus

"RECRUITING"

protocolSection.designModule.phases

["PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct

null

Study condition terms

• IBS (Irritable Bowel Syndrome) (protocolSection.conditionsModule.conditions)
• IBS-D (Diarrhea-predominant) (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['low dose for IBS-D'], 'description': 'RNIB21 containing rifaximin 66mg + N-acetylcysteine 560mg three times daily', 'name': 'rifaximin 66mg + N-acetylcysteine 560mg three times daily', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['high dose for IBS-D'], 'description': 'RNIB21 containing rifaximin 132mg + N-acetylcysteine 560mg three times daily', 'name': 'RNIB21 containing rifaximin 132mg + N-acetylcysteine 560mg three times daily', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['placebo'], 'description': 'placebo three times daily', 'name': 'Placebo', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

• rifaximin 66mg + N-acetylcysteine 560mg three times daily (protocolSection.armsInterventionsModule.interventions[].name)
• RNIB21 containing rifaximin 132mg + N-acetylcysteine 560mg three times daily (protocolSection.armsInterventionsModule.interventions[].name)
• Placebo (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.